Zhongxin Finance, January 23. On the 23rd, Changchun High-tech issued an announcement on abnormal fluctuations in stock trading, saying that the impact and extent of the centralized drug procurement in Guangdong Province on the company has not yet been determined.
The announcement shows that within three consecutive trading days (January 19, 2022, January 20, 2022, and January 21, 2022), the cumulative deviation of the daily closing price of Changchun Hi-Tech has reached -20%. The relevant provisions of the Exchange belong to the abnormal fluctuation of stock trading.
Changchun Hi-Tech stated that the centralized procurement of drugs in Guangdong Province has not yet officially started the bidding process, and the specific impact on the company's performance will also depend on the actual participation of Jinsai Pharmaceutical in the bidding, the results of the selection and the selection price, etc. The impact of this centralized procurement on the company and the magnitude of the impact has not yet been determined.
(Finish)